LEIDEN, Netherlands & CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will participate in the RNA Editing Summit, June 18-20, 2024, in Boston, Mas
… ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting LEIDEN, … it will present new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including the first …
… ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its … patent directed to its ADAR-mediated RNA editing platform Axiomer™. The opposition was filed in September 2023 with the …
… Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic … leading to meaningful changes in biomarkers in NHPs using Axiomer™ RNA Editing Oligonucleotides Preclinical proof of …
… ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit … of ProQR will present our proprietary RNA Base Editing Axiomer ® Technology including editing efficiency in various models. “Our Axiomer ® RNA base editing platform uses the body’s own …
In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas; update on initial pipeline targets expected in late 2022/early 2023
Additi
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG).
… R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology Key program … the unmet need in DEB and the current treatment landscape. Axiomer®: ProQR will introduce its novel, proprietary RNA …